Amedisys — Q4 2019 Earnings Presentation
22 slides from Amedisys's earnings presentation, Feb 18, 2020
Slide 1: Fourth Quarter and Year End 2019 Earnings Call Supplemental Slides
Amedisys Fourth Quarter and Year End 2019 Earnings Call Supplemental Slides February 19th, 2020 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: A Look Back: FY 2019 Accomplishments
A Look Back FY 2019 Accomplishments (as compared to FY 2018 unless otherwise noted) Clinical Distinction Maintained at least 91% of all Home Health care centers achieving 4.0+ Quality of Patient Care star score Outperformed industry on all hospice item set (HIS) quality metrics Expanded care centers
Slide 4: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus and progress made during 4Q’19 Home Health*: Total same store admissions +4%. Total same store volume +4% Hospice: Admissions +1%, ADC +8% Personal Care: Billable hours / quarter -10% (including acquisitions) 1 Organic Growth Quality: Amedisys Apr’20 p
Slide 5: Amedisys 2020 New Initiatives
Amedisys 2020 New Initiatives Our strategy remains the same (Clinical Excellence, Employer of Choice, Operational Excellence, Driving Growth); however, in 2020 we have several new initiatives that will be of focus Scale Personal Care Network CCH PDGM Clinical Excellence, Employer of Choice, Operatio
Slide 6: Highlights and Summary Financial Results (Adjusted): 4Q 2019
Highlights and Summary Financial Results (Adjusted): 4Q 2019(1) Home Health total same store volume +4%, total same store admissions +4%. Hospice same store admissions +1% Amedisys Consolidated Revenue Growth: +15% EBITDA: $52.2M (+19%) EBITDA Margin: 10.4% (+30 bps) EPS: $0.94 (+3%) 4Q’19 Net debt:
Slide 7: Our revenue sources: 4Q'19
Our revenue sources: 4Q’19 Medicare FFS: Paid episodically over a 60-day episode Private Episodic: MA and Commercial plans who pay us over a 60-day episode. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per
Slide 8: Home Health and Hospice Segment (Adjusted) – 4Q 2019
Home Health and Hospice Segment (Adjusted) – 4Q 2019(1) Revenue per Episode up +0.9% Recert rate down 100 bps Y/Y CPV up +$1.90 (+2.1%, raises effective 8/1) EBITDA as a % percentage of revenue: +90 bps Visits per Episode down 0.7 to 17.0 Home Health Highlights Same store average daily census (ADC)
Slide 9: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 100 basis points Home Health segment G&A: 70 bps increase as % of revenue - 40 bps due to change in staffing model (reclass of Clinical Manager Assistant role from Cost of Revenue
Slide 10: Industry Leading Quality Scores
Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric JUL 19 Release OCT 19 Release JAN 20 Release APR 20 PREVIEW Quality of Patient Care 4.27 4.28 4.27 4.26 Entities at 4+ Stars 85% 88% 86% 86% Metric APR 19 Release JUL 19
Slide 11: Hospice Quality: Moving Towards Best-in-Class Hospice Quality
Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality
Slide 12: Cost per Visit Components
Components 4Q’18 3Q’19 4Q’19 YoY Variance Detail Initiatives Salaries $62.79 $63.24 $64.18 $1.39 YoY increase due to planned wage increases partially offset by improvements in clinical utilization and optimization of discipline mix Staffing mix optimization, productivity and scheduling improvement i
Slide 13: Driving Top Line Growth
Driving Top Line Growth Continuing growth in all three lines of business Home Health Total Volume Hospice ADC Personal Care Total Hours / Quarter *Includes impact of East Tennessee (5/1/18) and Bring Care Home (10/1/18) acquisitions
Slide 14: Debt and Liquidity Metrics
Debt and Liquidity Metrics ~0.7x net leverage – revolver completely paid off during 2019 post Compassionate Care acquisition ex. Asana borrowing Net debt defined as total debt outstanding ($245.7M) less cash & restricted cash balance ($96.5M). Leverage ratio (net) is defined as net debt divided by l
Slide 15: Cash Flow Statement Highlights
Cash Flow Statement Highlights (1) Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
Slide 16: Income Statement Adjustments
Income Statement Adjustments (1) The financial results for the three-month periods ended December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP
Slide 17: 2020 Guidance
2020 Guidance
Slide 18: Amedisys 2020 Preliminary Guidance
Amedisys 2020 Preliminary Guidance 2019 Actual Performance 2020 Guidance Revenue Adjusted EBITDA $225.3M $1,962M Adjusted Earnings per Share $4.40 $250M - $260M $2,115M - $2,160M $4.90 - $5.13
Slide 19: 2020 Guidance Considerations
2020 Guidance Considerations Growing and thriving through Patient Driven Groupings Model (PDGM), continued organic and inorganic growth in Hospice and investments in our people and future innovations drive 2020 performance Amedisys Consolidated Home Health Hospice Personal Care Tax rate ~26% Cash ta
Slide 20: Reimbursement Outlook
Reimbursement Outlook Reimbursement Impact for Home Health and Hospice Home Health Hospice 2019 Final Rule (PDGM – Behavioral Assumpitons) (4.36%) Estimated AMED-Specific Impact (Claims from Jan – Sept 2019) (2.8%) 2020* Market Basket Update 3.0% Productivity / Other Adjustment (0.4) Estimated Indus
Slide 21: Impact of Health Insurance and Raises
Impact of Health Insurance and Raises
Slide 22: Our Path Forward: 2020, 2021 & Beyond
Our Path Forward: 2020, 2021 & Beyond Headwind from PDGM in first quarter Minimal impact from PDGM cost levers Integration of Hospice assets underway – ramping towards legacy AMED growth and profitability Ramping PDGM cost levers (50%/50% LPN and PTA utilization) and full impact of utilization manag